Razodex Capsules 30Mg
Brand : getz pharma pakistan
Requires Prescription (YES/NO)
Gastroesophageal Reflux Disease
How it works
Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase at the secretory surface of the gastric parietal cell. Dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production.
USAGE AND SAFETY
Common : Diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting and flatulence. Less Common : Anemia, lymphadenopathy, angina, arrhythmia, bradycardia, chest pain, edema, myocardial infarction, palpitation, tachycardia, ear pain, tinnitus, vertigo, goiter, eye irritation, eye swelling, abdominal discomfort, abdominal tenderness, abnormal feces, anal discomfort, Barrett’s esophagus, bezoar, abnormal bowel sounds, breath odor, colitis microscopic, colonic polyp, constipation, dry mouth, duodenitis, dyspepsia, dysphagia, enteritis, eructation, esophagitis, gastric polyp, gastritis, gastroenteritis, gastrointestinal disorders.
Rilpivirine, atazanavir and nelfinavir , Saquinavir , Warfarin , Methotrexate , Digoxin , iron salts, erlotinib, dasatinib, nilotinib, mycophenoloate mofetil, ketoconazole/itraconazole , Tacrolimus , tetrahydrocannabinol (THC) , CYP2C19 or CYP3A4 Inducers (St. John’s Wort, rifampin) , CYP2C19 or CYP3A4 Inhibitors (Voriconazole)
Dexlansoprazole is indicated in patients 12 years of age and older:• For healing of all grades of erosive esophagitis (EE) for up to eight weeks.• To maintain healing of EE and relief of heartburn for up to six months.• For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.
When not to Use
Dexlansoprazole is contraindicated: • In patients with known hypersensitivity to dexlansoprazole or to any excipient of the product. • With rilpivirine-containing products. • In patients with severe hepatic impairment.
Use of proton pump inhibitors (PPIs) may increase risk of Clostridium difficile-associated diarrhea, especially in hospitalized patients. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.
Increased incidence of osteoporosis-related bone fractures of the hip, spine or wrist may occur with proton pump inhibitor (PPI) therapy. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the conditions being treated. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines.
Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics or other drugs known to cause hypomagnesemia.
Prolonged treatment may lead to vitamin B12 malabsorption and subsequent vitamin B12 deficiency.
Always consult your physician before using any medicine.
Store this medicine at room temperature, away from direct light and heat.